Company: RVRC
Filing Date: 2025-10-03
Form Type: S-1/A
Source: 0001213900-25-096094
Chunk: 230

Company: Revium Rx.
Filing Date: 2025-10-03
Form: S-1/A
Chunk 230
---
 the acquisition and are therefore not comparable to the financial statements of the Predecessor period that are not presented on the
same full step-up basis.

Recently Issued Accounting Pronouncements not yet adopted

In December
2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740), Improvements to Income Tax Disclosures, which requires disaggregated information
about the effective tax rate reconciliation as well as information on income taxes paid. The guidance will be effective for the Company
for annual periods beginning January 1, 2025, with early adoption permitted. The Company is currently evaluating the impact on its consolidated
financial statement disclosures.

In November
2024, the FASB issued ASU 2024-03 “Income Statement (Topic 220): Reporting Comprehensive Income - Expense Disaggregation Disclosures” (“ASU
2024-03”), which requires more detailed information about specified categories of expenses presented on the face of the income
statement, in addition to disclosures about selling expenses. ASU 2024-03 is effective for fiscal years beginning after December 15,
2026, with early adoption permitted. The amendment may be applied either prospectively to financial statements issued for reporting periods
after the effective date or retrospectively to all prior periods presented in the financial statements. The Company is currently evaluating
ASU 2024-03 to determine the impact it may have on its consolidated financial statements and related disclosures.

<div align='center'>F-40</div>

REVIUM RX.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

U.S. dollars in thousands

| NOTE 3: - | UNAUDITED INTERIM FINANCIAL STATEMENTS |

The accompanying
interim consolidated balance sheet as of June 30, 2025, the interim consolidated statements of comprehensive loss and the interim consolidated
statements of cash flows for the six months ended June 30, 2025, and 2024, as well as the interim consolidated statement of changes in
equity for the six and three months ended June 30, 2025, are unaudited.

These
unaudited interim consolidated financial statements have been prepared in accordance with generally accepted accounting principles in
the United States (“U.S. GAAP”) and applicable rules and regulations of the Securities and Exchange Commission regarding
interim financial reporting. In management’s opinion, the unaudited interim consolidated financial statements include all adjustments
of a